Human Solid Oral Dose Vaccine Delivery
The recent COVID-19 pandemic highlighted the need for high-capacity vaccine solutions. PlantPharm BioMed’s production technology can deliver on this need transforming existing hypodermically injected vaccines to an oral solid dose vaccine with comparatively low production costs, and high production scalability and flexibility. Additional potential vaccines may address: SARS-CoV2 (COVID-19), Hepatitis B, HPV (Human Papilloma Virus), RSV (Respiratory Syncytial Virus), Meningitis, Malaria and many others.
The Breakthrough
PlantPharm BioMed’s process grew plants with the world’s first oral solid dose Hepatitis B Vaccine which was proven effective in a double-blind, placebo-based, human clinical trial. The results of this human trial supports the process as an effective mucosal vaccine administered in oral form. This production system is game-changing for biopharmaceutical production marketplace. The ability to grow and deliver vaccines, and other biopharmaceuticals using plants as the production medium has now become reality and makes it possible to delivery any number of human vaccines in an Oral Solid Dose format.
The PlantPharm BioMed platform provides many benefits when compared to traditional hypodermic needle vaccine delivery including:
Solid oral delivery of vaccines vs. hypodermic injection
Comparatively low-cost, shelf-stable and easy to handle and ship.
Highly-scalable resulting in millions of doses of vaccines at lower cost per dose production.
Removal of contaminants like prions and viroids from biopharmaceuticals.
Stable replication eliminates variability.
Mucosal vaccinations are most effective.
Human Therapeutic Delivery
Along with Infectious Disease vaccines that are the first clinically proven example of PlantPharm’s capabilities, another 500 biopharmaceutical drugs are deemed to be compatible with PlantPharm’s manufacturing platform technology thus providing a target-rich marketplace for the Company. As work is done to develop Cancer vaccines and therapeutics, these also become potential targets for PlantPharm’s platform technology, for which work is already being done. Ten of the highest revenue biopharmaceuticals projected for 2020 are suitable for production in potato plants using the PlantPharm platform technology as either monoclonal antibodies or therapeutic proteins or peptides.
